期刊文献+

急性冠脉综合征患者前蛋白转化酶枯草溶菌素9水平及临床意义 被引量:6

下载PDF
导出
摘要 目的探讨前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin/kexin type 9,PCSK9)在急性冠脉综合征(acute coronary syndrome,ACS)患者中的水平及临床意义。方法选取2017年6月至2018年6月首都医科大学附属北京天坛医院急诊内科就诊的经冠状动脉造影确诊为冠状动脉粥样硬化性心脏病患者118例,其中ACS组62例,稳定型心绞痛(stable angina pectoris,SAP)组56例,另取同期做冠状动脉造影检测、排除冠心病患者40例作为对照组。于造影前采血测定高敏C反应蛋白(high-sensitivity c-reactive protein,hs-CRP)、甘油三酯(triacylglycerol,TG)、总胆固醇(total cholesterol,TC)、高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)、低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)、载脂蛋白(apo)-A1、apo-B、空腹血糖(fasting blood-glucose,FPG)和血肌酐(serum creatinine,Scr)水平;通过酶联免疫吸附测定的方法检测血浆PCSK9水平。结果 ACS组PCSK9、hs-CRP、LDL-C、TC、apo-B和FPG水平明显高于SAP组和对照组(P<0.05),HDL-C低于对照组(P<0.05);SAP组PCSK9、LDL-C、apo-B水平高于对照组。ACS组和SAP组患者的血浆PCSK9水平与hs-CRP、LDL-C、TC、apo-B均呈正相关(r分别为0.386、0.561、0.509、0.460,均P<0.05)。ACS组3支病变患者的PCSK9水平高于单支病变者。结论血清PCSK9参与冠状动脉粥样硬化的发生发展过程,PCSK9可能通过参与血管壁炎症反应及脂质代谢促进ACS的发生,PCSK9水平与ACS患者病变严重程度相关。
出处 《中国临床医生杂志》 2019年第7期786-788,共3页 Chinese Journal For Clinicians
  • 相关文献

参考文献4

二级参考文献52

  • 1Abifadel M, Rabes J P, Boileau C, et al. After the LDL receptor and apolipoprotein B, autosomal dominant hypercholesterolemia reveals its third protagonist: PCSK9 [ J]. Ann Endocrinol (Paris) ,2007, 68(2-3) : 138-146.
  • 2Martin B, Solanas-Barca M, Garcia-Otin A L, et al. An NPC1L1 gene promoter variant is associated with autosomal dominant hypercholesterolemia[ J]. Nutr Metab Cardiovasc Dis, 2010,20(4) :236-242.
  • 3Varret M, Abifadel M, Rabes J P, et al. Genetic heterogeneity of autosomal dominant hypercholesterolemia [ J ]. Clin Genet, 2008,73(1 ) :1-13.
  • 4Lopez D. PCSK9 : an enigmatic protease [ J]. Biochim Biophys Acta, 2008,1781 ( 4 ) : 184-191.
  • 5Lambert G, Charlton F, Rye K A, et al. Molecular basis of PCSK9 function [J]. Atherosclerosis,2009, 203 ( 1 ) : 1-7.
  • 6Homer V M, Marais A D, Charhon F, et al. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa[J]. Atherosclerosis,2008,196(2) :659-666.
  • 7Hallman D M, Srinivasan S R, Chen W, et al. Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood(from The Bogalusa Heart Study) [ J]. Am J Cardiol,2007, 100( 1 ) : 69-72.
  • 8Cohen J, Pertsemlidis A, Kotowski I K, et al. Low LDL cholesterol in individuals of African descent resulting from frequerit nonsense mutations in PCSK9 [ J]. Nat Genet,2005,37 (2) :161-165.
  • 9Mayne J, Dewpura T, Raymond A, et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans [ J ]. Lipids Health Dis,2008,7:22.
  • 10Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) : hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration [ J ]. Hepatology, 2008,48 ( 2 ) : 646 -654.

共引文献76

同被引文献63

引证文献6

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部